6th
International Congress on
Myeloproliferative Diseases and
Myelodysplastic Syndromes

November 3-4, 2011
New York, New York
New York Marriott at The Brooklyn Bridge

Chair and Convener:
Richard T. Silver, MD, FACP
Weill Cornell Medical College
NewYork-Presbyterian Hospital
Weill Cornell Medical Center
New York, New York

Co-Chair:
Jerry L. Spivak, MD, FACP
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Endorsed by:
Aplastic Anemia & MDS
INTERNATIONAL FOUNDATION

NewYork-Presbyterian
The University Hospital of Columbia and Cornell

mds foundation
the myelodysplastic syndromes foundation, inc.

Second Announcement and Call for Abstracts

EDUCATION IS THE BEST MEDICINE®
WWW.IMEDEX.COM
DEAR COLLEAGUE:

It is our pleasure to invite you to join us at the 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. The 2011 Congress, which will be held November 3-4 at the New York Marriott at the Brooklyn Bridge, promises to be our most exciting and interactive meeting yet!

Since the inaugural Congress in 2001, this meeting has grown to nearly 600 attendees and has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. We will focus on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia and myelodysplasia.

With its diverse mix of oncologists, hematologists, surgeons, and pathologists, this will be a great place to interact with your colleagues and learn from internationally renowned faculty.

We look forward to welcoming you in November to New York as the Fall brings its special beauty to this exciting international city!

Sincerely,
Richard T. Silver, MD, FACP
Chair and Convener
Jerry L. Spivak, MD, FACP
Co-Chair

OBJECTIVES

After successful completion of this course, participants should be able to:

- Review the classification and pathogenesis of myelodysplastic diseases
- Discuss current best practices in the treatment of MDS
- Comment on novel drugs in MDS, with a focus on management of iron overload
- Review new prognostic classifications and their relevance to allogeneic transplantation in primary myelofibrosis
- Discuss novel markers and therapies beyond JAK2 in myelofibrosis
- Review important genetic abnormalities in myeloproliferative disorders
- Comment on the clinical significance of mutations in polycythemia vera
- Identify the importance of cerebral circulation in outcomes related to polycythemia vera
- Discuss molecular drug targets in myeloproliferative disorders
- Review risk factors for thrombosis in MPDs
- Review the most current updates in the biology and pathogenesis of CML
- Improve response monitoring and overcome drug resistance to improve CML outcomes
- Review the management of CML in pregnancy
- Discuss second and third generation tyrosine kinase inhibitors and their current and future positioning within the current treatment armamentarium
- Review treatment of accelerated and blast phase CML disease
- Debate the optimal role of transplantation in CML

CONTINUING MEDICAL EDUCATION

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 13 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

WHO SHOULD ATTEND

This educational activity is specifically designed for hematologists, interns, medical and radiation oncologists, and other pathologist, surgeons and healthcare professionals (nurses, pharmacists) interested and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.

SUPPORT

The following companies have provided an educational grant in support of this Congress:

Bronze

Celtene

Incyte

Several options are available to companies interested in supporting this Congress.

For more information, please contact Imedex at +1 (770) 751 7332 or by email at cme@imedex.com.

CALL FOR EXHIBITORS

Exhibit space is available to companies interested in participating in this congress.

For more information, please contact Imedex at +1 (678) 242 0719 or by email at exhibits@imedex.com.
6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

FACULTY

Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy

John M. Bennett, MD
University of Rochester Medical Center
Rochester, New York

Stefan Constantinescu, MD, PhD
Ludwig Institute for Cancer Research
Brussels, Belgium

Jorge Cortes, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Nicholas C. P. Cross, PhD, FRCPath
University of Southampton
Wessex Regional Genetics Laboratory
Salisbury District Hospital
Wilts, United Kingdom

Michael Deininger, MD, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah

Pearlie K. Epling-Burnette, PharmD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Sergio A. Giralt, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

John Goldman, MD, FRCP
Imperial College School of Medicine
Hammersmith Hospital
London, United Kingdom

Anthony R. Green, PhD, FRCPath
Cambridge Institute for Medical Research, Wellcome Trust, Addenbrooke’s Hospital
Cambridge, United Kingdom

Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der Universität Heidelberg Mannheim Mannheim, Germany

Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, New York

Hagop M. Kantarjian, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Jean-Jacques Kiladjian, MD, PhD
Saint-Louis Hospital and Paris University, Hospital Saint-Louis Centre d’Investigation Clinique Paris, France

Ross L. Levine, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Alan F. List, MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Ruben A. Mesa, MD
Mayo Clinic
Scottsdale, Arizona

Tariq Mughal, MD, FRCP
University of Colorado Health Sciences Center
Denver, Colorado

Vesna Najfeld, PhD
The Mount Sinai School of Medicine
New York, New York

Heike L. Pahl, PhD
Freiburg University Medical Center Center for Clinical Research Freiburg, Germany

Animesh Pardanani, MBBS, PhD
Mayo Clinic Rochester, Minnesota

Josef T. Prchal, MD
University of Utah Health Sciences Center Salt Lake City, Utah

Gail J. Roboz, MD
Weill Medical College of Cornell University
New York, New York

Andrew I. Schafer, MD
Weill Cornell Medical College New York-Presbyterian Hospital New York, New York

Richard T. Silver, MD, FACP
Weill Cornell Medical College New York-Presbyterian Hospital/ Weill Cornell Medical Center New York, New York

Radek Skoda, MD
University Hospital Basel Basel, Switzerland

Jerry L. Spivak, MD, FACP
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore, Maryland

Alessandro M. Vannucchi, MD
University of Florence Florence, Italy

Srdan Verstovsek, MD, PhD
The University of Texas M. D. Anderson Cancer Center Houston, Texas

CONGRESS ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, Georgia, 30009, USA
Tel.: +1 (770) 751 7332 / Fax: +1 (770) 751 7334
Email: meetings@imedex.com

November 3-4, 2011
New York, New York
New York Marriott at The Brooklyn Bridge
THURSDAY, NOVEMBER 3, 2011

8:00 am
Introduction
Richard T. Silver, MD, FACP

Session I: Myelodysplastic Syndromes
Chairs: John M. Bennett, MD, and Alan F. List, MD

8:20 am Program overview
John M. Bennett, MD, and Alan F. List, MD

8:25 am Translating molecular genetics into therapeutic targets: Has individualized treatment arrived?
Nicholas C.P. Cross, PhD, FRCPath

8:50 am Riskadaptive strategies for MDS management
John M. Bennett, MD

9:15 am The 5q syndrome: Molecular targets of disease and therapy
Alan F. List, MD

9:40 am Immune signature-guided immunodepletion therapy in MDS
Pearlie K. Epling-Burnette, PharmD, PhD

10:05 am Coffee break

10:25 am Positioning hypomethylating agents and “the pipeline ahead”
Gail J. Roboz, MD

10:50 am Progress in replacing the stem cell: Allogeneic HSCT
Sergio A. Giralt, MD

11:15 am Lunch Symposium: Untangling the Controversy – Impact and Management of Iron Overload in MDS
Supported by Novartis

Session II: Chronic Myeloid Leukemia
Chairs: John Goldman, MD, FRCP and Rudiger Hehlmann, MD, PhD

1:05 pm Update on the biology of CML
John Goldman, MD, FRCP

1:35 pm Current treatment of CML with imatinib, dasatinib, and nilotinib
Hagop M. Kantarjian, MD

2:05 pm New drugs in the treatment of CML
Jorge Cortes, MD

2:35 pm How should patients be monitored? Current usage of FISH, PCR, mutation analysis, and plasma OCT-1
Michael Deininger, MD, PhD

3:05 pm Coffee break

3:25 pm Current management of accelerated- and blast-phase disease
Rudiger Hehlmann, MD, PhD

4:00 pm Current status of bone marrow transplantation in CML
Sergio A. Giralt, MD

4:30 pm Abstract presentations and discussion
Chair: Jerry L. Spivak, MD, FACP
Co-chair: Tariq Muhal, MD, FRCP
Reviewers: Vesna Najfeld, PhD and Ruben A. Mesa, MD

5:15 pm Closing notes

5:30 pm Adjourn

To Register: Register online at www.imedex.com, or by calling Imedex at +1 (678) 242 0906.
Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
After October 27, 2011 only credit card payments will be accepted for pre-registration.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available to Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than October 27, 2011. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

REGISTRATION

<table>
<thead>
<tr>
<th></th>
<th>$ 325</th>
<th>$ 425</th>
<th>$ 525</th>
<th>$ 199</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payment received by September 1, 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td>$ 425</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payment received by October 27, 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full / Onsite</td>
<td>$ 525</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payment received after October 27, 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Discount</td>
<td>-$ 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physicians only**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nurses / Residents / Students*</td>
<td></td>
<td>$ 199</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Proof of eligibility must accompany registration
** Cannot be combined with any other discounts

TO REGISTER, VISIT www.imedex.com, or call +1 (678) 242 0906
Session III: Myeloproliferative Neoplasms

Chairs: Jerry L. Spivak, MD, FACP and Andrew I. Schafer, MD

8:30 am Clonal evolution and the MPN stem cell hierarchy
Radek Skoda, MD

9:00 am JAK/STAT signalling and the MPN phenotype
Anthony R. Green, PhD, FRCP, FRCPaPath

9:30 am Targeting JAK2 V617F and the signaling pathways synergizing with it
Stefan Constantinescu, MD, PhD

10:00 am Coffee break

10:15 am The molecular basis of polycythemia vera
Jerry L. Spivak, MD, FACP

10:45 am Secondary erythrocytosis
Josef T. Prchal, MD

11:15 am Using novel MPN biomarkers wisely: Strategies for diagnosis and clinical trials
Heike L. Pahl, PhD

11:45 am Drugs for polycythemia vera therapy in 2011: Balancing benefits and risks
Jean-Jacques Kiladjian, MD, PhD

12:15 pm Lunch

Session IV: Myeloproliferative Neoplasms

Chairs: Richard T. Silver, MD, FACP and Ross L. Levine, MD

1:15 pm Therapeutic targets for reducing the thrombosis rate in the MPN
Tiziano Barbui, MD

1:45 pm Clinical correlates of MPN mutations
Alessandro M. Vannucchi, MD

2:15 pm The potential of drug combinations in MPN treatment
Ronald Hoffman, MD

2:45 pm Update on the treatment of myeloproliferative diseases with current JAK2 inhibitors
Srđan Verstovsek, MD, PhD

3:15 pm Coffee break

3:30 pm Assessing symptoms and response in MPN patients – Lessons from current and future therapies
Ruben A. Mesa, MD

4:00 pm Anemia responses in myelofibrosis: Role of IMiDs and other therapies
Animesh Pardanani, MBBS, PhD

4:30 pm Treatment of early myelofibrosis with interferon alpha-2b
Richard T. Silver, MD, FACP

5:00 pm Closing notes

5:30 pm Adjourn
CALL FOR ABSTRACTS

Participants interested in presenting data should first register or log in, then submit abstracts online by August 18, 2011 at www.imedex.com. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course and scheduled for oral or poster presentation. For additional information please see the Congress website.

Acceptance notifications and guidelines for poster or oral presentation will be sent by September 15, 2011. Authors of accepted abstracts who have not registered will have until October 21, 2011 to do so at the rate of $325. After this date, abstracts without registered presenters will be disregarded.

Submit your abstract online

Go to www.imedex.com, select this Congress, and follow the instructions in the “Abstracts” section.

IMPORTANT DATES

<table>
<thead>
<tr>
<th></th>
<th>August 18, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract Submission Deadline</td>
<td></td>
</tr>
<tr>
<td>Discounted Registration Deadline</td>
<td>September 1, 2011</td>
</tr>
<tr>
<td>Abstract Notifications Mailed</td>
<td>September 15, 2011</td>
</tr>
<tr>
<td>Abstract Presenter Registration Deadline</td>
<td>October 21, 2011</td>
</tr>
<tr>
<td>Regular/Onsite Registration Deadline</td>
<td>October 27, 2011</td>
</tr>
<tr>
<td>Presentation Dates</td>
<td>November 3-4, 2011</td>
</tr>
</tbody>
</table>

TO REGISTER, VISIT www.imedex.com, or call +1 (678) 242 0906

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, Imedex EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. Imedex FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

© 2011 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.